PIN43: THE EFFECT OF HEALTH PERCEPTION IN MODIFYING TOTAL HEALTH CARE EXPENDITURES WITHIN AN IMMUNIZED ELDERLY UNITED STATES POPULATION  by Patterson, ME
267Abstracts
144,000 in Ontario) over a 10-year horizon, from provin-
cial Ministry of Health (MoH) and societal perspectives.
For Québec, costs and beneﬁts of adding acellular per-
tussis to combined diphtheria-tetanus vaccine (DacPT) in
schools were compared to the current practice of admin-
istering the diphtheria-tetanus vaccine only. In Ontario,
we assumed co-administration of the new vaccine with
Hepatitis B vaccine. Efﬁcacy and utilisation data (vacci-
nation, management of pertussis infection and hospital-
ization) were derived from the literature. Productivity 
loss of parents and older adolescents was estimated. 
Standard cost lists were used (CAD$), discounted at 3%.
RESULTS: From the MoH perspective, the expected addi-
tional cost of DacPT per adolescent over 10 years was
$5.80 for Québec and $3.19 for Ontario; the respective
expected incremental cost-effectiveness ratios were
$184.83 and $101.73 per pertussis case avoided. From
the societal perspective, the additional 10-year cost would
be $2.70/adolescent with an expected incremental cost-
effectiveness ratio of $86.03 per case avoided in Québec,
while in Ontario there would be savings of $6.67 per 
adolescent. In Québec, more than 2760 pertussis cases
would be prevented, and 4520 in Ontario. CONCLU-
SION: This study suggests that administering a booster
dose of DacPT at age 12, may reduce the burden of per-
tussis at a reasonable cost, potentially with savings to
society. The impact of implementing the new programme
is lower in Ontario, as it assumes additional savings by
shifting administration of the vaccine from the physician
to the school.
PIN42
COST OF VARICELLA IN POLAND
Glogowski CA1, Gierczynski JM1, Splawinski J2
1GlaxoSmithKline Pharmaceuticals S.A, Warsaw, Poland;
2Independent Centre for Economic and Pharmaceutical
Research, Warsaw, Poland
OBJECTIVE: To assess the cost of varicella infections in
Poland from payers and societal perspectives as a part of
evaluation of cost-effectiveness of varicella vaccination.
Background: Mass vaccination against varicella is pos-
sible as safe, effective, and providing life-long protection
vaccine (Varilrix) became available and the possibility
that vaccination would shift varicella infections to older
age groups seems remote. METHODS: We collected data
of medical and non-medical resources used by patients
suffering from varicella. Medical costs were taken from
local health services price lists and retail prices of drugs
were used. All local prices were changes into dollars. 
Epidemiological data were taken from national health
statistics data for 2000: incidence 331.3/100,000, preva-
lence 12,8016, hospitalisations 1008 and 2 deaths. Main
assumptions (based on experts panel): 2 doctors visits,
antihistaminics, analgesics, antipyretic, antiviral, and
antibiotics, and 4 days loss of productivity—all for one
case. RESULTS: Direct cost per case accounted to 49.12
USD and indirect cost per case, to 91.64 USD. Total cost
per case was: 140.76 USD. Total annual cost per popu-
lation was 11,050,867 USD with 5,771,872 USD of
direct costs and 5,278,995.7 USD of indirect costs.
CONCLUSION: Varicella has considerable burden on
Polish health care system. As safe and long-term 
effective vaccine against varicella is available in Poland,
cost-effectiveness and cost-beneﬁt analyses will be 
performed.
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OBJECTIVES: Even though inﬂuenza vaccinations have
been shown to decrease morbidity, mortality, and hospi-
talization costs among seniors in the United States, vac-
cination rates among seniors remain below national
standards. Positive health perceptions may decrease
immunization seeking behavior, and indirectly increase
medical expenditures. This analysis investigates the main
effect of immunization status as well as the interaction
between health perception and immunization status on
total medical expenditures in the elderly. METHODS:
Participants included 1350 individuals aged 65 and older
with non-zero total medical expenditures who responded
to the 1996 University of Michigan Health Retirement
Survey (HRS) survey. Total medical expenditures were
measured as out-of-pocket or insurance spent between
1994 and 1996. Positive vaccination status was assigned
to individuals who self-reported receiving an inﬂuenza
shot between 1994 and 1996. Ordinary Least Squares
(OLS) was used to estimate medical expenditures in the
ﬁnal multivariate model. RESULTS: The vaccinated
elderly population had on average 35% higher total
medical expenditures than the non-vaccinated popula-
tion, after controlling for perceived health status, func-
tional limitations, age, gender, race, income, education,
and marital status. Self-reported health status did not
modify the association between vaccination status and
medical expenditures (F(4,1302) = 1.40, p = 0.2319).
CONCLUSIONS: Immunized seniors spend more on
medical care than non-immunized seniors, suggesting that
seniors seeking immunizations utilize the health system
more frequently. Perceived health status was not found to
be an effect modiﬁer, suggesting that the association
between a senior’s immunization status and their medical
costs is independent of how they perceive their own
health. Since this cross-sectional analysis has limitations
in drawing conclusions of the effect of immunizations 
on medical expenditures, future studies need to employ 
longitudinal analysis to further investigate the role of 
perceived health status among non-vaccinated elder 
populations. Understanding this role will contribute to
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improving national inﬂuenza vaccination rates among the
elderly.
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OBJECTIVE: To determine the cost of treating an inten-
sive care unit (ICU) patient with severe sepsis who expires
while hospitalized at The Johns Hopkins Hospital (JHH),
prior to the introduction of drotrecogin alfa (activated)
for the treatment of severe sepsis. METHOD: The study
utilized a cost-of-illness methodology. Data were col-
lected through retrospective chart review. Patients with
sepsis were identiﬁed based on their discharge summary
in an integrated patient care database at JHH. Patient
selection included those hospitalized between October 1,
2000 and September 30, 2001, in an adult ICU, who
expired prior to hospital discharge. A random sample of
these patients was chosen for chart review. Chart review
identiﬁed patient status based on the PROWESS study
inclusion criteria for the diagnosis of severe sepsis. Cost-
of-illness calculation included direct medical costs (med-
ications, hospital days, and ICU days). The cost to the
hospital was calculated using the cost-to-charge ratio spe-
ciﬁc for JHH. Indirect costs were not included. RESULTS:
A total of 60 patients were included in the study. The
mean total hospital, non-ICU, ICU, and sepsis-related
lengths of stay were 24, 8, 16, and 18 days, respectively.
Patients spent a mean of 67% of hospitalized days in 
the ICU. The mean total hospitalization cost for a 
patient with severe sepsis who expires was approximately
$54,000 and the mean sepsis-related hospitalization cost
for one of these patients was approximately $40,000. The
mean total costs per day (medication costs per day in
parentheses) for the entire hospitalization, non-ICU stay,
ICU stay, and sepsis-related stay were $2270 ($313),
$1512 ($210), $2649 ($364), and $2245 ($339), respec-
tively. CONCLUSION: Sepsis is a condition that has a
signiﬁcant impact on patient mortality and hospital costs.
The results of this study will be used to monitor the effect
of the use of drotrecogin alfa (activated) for the treatment
of severe sepsis at JHH.
INFECTION—Quality of Life/Preference Based
Outcomes
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OBJECTIVE: CPCRA-042/CTN-02, was a binational,
randomized, open label trial in patients with advanced
HIV receiving either Nelﬁnivir (NLF) or Ritonavir (RTV).
A pharmacoeconomic (PE) sub-study of consenting 
Canadian participants prospectively captured health
resource utilization (HRU) and Quality of Life (QOL)
data. Our objective was to assess costs, effects and incre-
mental cost-effectiveness of NLF compared to RTV as
Protease Inhibitor therapy. METHOD: The PE sub-study
recruited from 13 Canadian sites. Data collected included
HRU and QOL as measured by a VAS and SF12 every 4
months. Costs were estimated using the St. Paul’s Hospi-
tal (SPH) formulary, SPH Cost Model, and BCMA fee
schedule. Using intent to treat analysis, the annual incre-
mental cost effectiveness ratio (ICER) was calculated.
RESULTS: In the main study, there was no difference in
the time to clinical progression, immunologic or virologic
responses between the two study arms. In PE sub-study,
137 patients were randomized: NLF (n = 71) or RTV 
(n = 66). The median (Q1–Q3) baseline patient age was
38 years (33–44), with median CD4+ count of 36/mm3
(12–70). Total follow-up time was ≥3 years. Preliminary
results show mean (SD) ﬁrst year annual total cost for
NFV patients to be $26,099 (14,800) and $20,475 (7591)
for RTV patients; p < 0.001. QOL scores showed no sig-
niﬁcant difference among groups at one year. The number
of patients switching initially assigned study drug due to
toxicity was lower for the NLF group 19 (27%) vs. 26
(39%) at one year and 8 (12%) vs. 24 (36%) in the ﬁrst
8 months. The annual ICER per switch avoided equaled
$24,071 per patient. CONCLUSION: The overall total
cost and tolerability with assigned therapy were both
higher for NLF. Given equal efﬁcacy and immunologic
response, the choice for one drug over the other as initial
therapy depends on the importance placed on tolerability
of the start-up regimen and potential for the emergence
of drug resistance.
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OBJECTIVES: Even with the advent of new pharma-
cotherapies (e.g., HAART) that minimize inpatient care,
HIV/AIDS patients are sometimes hospitalized for acute
problems. Patients’ responses to speciﬁc aspects of hospi-
talization determine their satisfaction and have implica-
tions for hospitals’ quality improvement efforts. The
objective of this study was to examine ratings of hospi-
talization experiences of HIV/AIDS inpatients and
compare them with ratings of other, non HIV/AIDS inpa-
tients. METHODS: A set of surveys from 78 patients dis-
charged from 32 US hospitals in 2001 was assembled.
Surveys contained 49 items pertaining to aspects of 
hospitalization as well as several patient demographic
items. Surveys had been pre-coded to include diagnostic
information (Diagnosis-Related Group (DRG)) and were
